Dual targets lead the metabolic health revolution. Tirzepatide (2023788-19-2) has become the king of drugs, empowering the global pharmaceutical industry to upgrade

▶ The global field of metabolic disease treatment has witnessed iterative breakthroughs. The GLP-1/GIP dual-target agonist track continues to explode. As a leading product in this field, Tirzepatide (tirzepatide, CAS number: In 2023788-19-2), with its unique dual-target synergy advantages, outstanding clinical efficacy and explosive market performance, it successfully claimed the title of the global "King of Drugs", becoming the core focus in the fields of pharmaceutical research and development, clinical application and chemical production, and promoting the entry of metabolic health treatment into a new era of "dual-target synergy".
Tirzepatide is an artificially synthesized long-acting GLP-1 (glucagon-like peptide-1) /GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, belonging to the polypeptide compound category. Its chemical formula is CHNOS, with a molecular weight of approximately 6,563.0 and a purity of over 98.0%. It appears as a white powder. It is highly soluble in water. At room temperature, it should be stored in a sealed container away from light to ensure its biological activity. Unlike single GLP-1 receptor agonists, Tirzepatide achieves synergistic effects by precisely targeting two key metabolic targets, GLP-1 and GIP. The GLP-1 receptor is responsible for suppressing appetite and delaying gastric emptying, while the GIP receptor can improve insulin sensitivity and reduce fat accumulation. The dual mechanism of action enables a leapfrog improvement in therapeutic effect. Meanwhile, through structural modification, the half-life in the body is prolonged, allowing for subcutaneous injection once a week, which significantly enhances patients' medication compliance.

▶ In the field of clinical application, the core value of Tirzepatide has been fully verified by multiple top clinical trials worldwide, forming a clinical application pattern led by the dual main lines of blood sugar reduction and weight loss. As an innovative drug for the treatment of type 2 diabetes, it effectively reduces the level of glycated hemoglobin (HbA1c) in patients by regulating insulin and glucagon secretion in a glucose-dependent manner. Relevant clinical trials have shown that a dose of 5-15 mg once a week can lower HbA1c by 1.8% to 2.1%, and the risk of hypoglycemia is significantly lower than that of traditional hypoglycemic drugs. In the field of weight loss, its advantages are even more prominent. The SURMOUNT 5 study published in the New England Journal of Medicine showed that at week 72, the average weight loss ratio of the Tirzepatide treatment group reached 20.2%, with an average weight loss of 22.8kg, significantly better than that of a single GLP-1 receptor agonist. It provides more efficient treatment options for obese and overweight people. In addition, Tirzepatide has achieved remarkable results in clinical research in areas such as cardiovascular protection, metabolism-related fatty liver disease (MASLD), and obesity-related respiratory disorders, further expanding its clinical application boundaries and demonstrating its all-round characteristic of "treating multiple diseases with one drug".

▶ In addition to its mature clinical applications, the scientific research potential of Tirzepatide is continuously being explored, and its application fields are constantly expanding. Research has found that this compound can pass through the blood-brain barrier and shows potential value in the study of neurodegenerative diseases, and is expected to provide new directions for the treatment of diseases such as Parkinson's disease and Alzheimer's disease. In the research on the treatment of metabolism-related fatty liver disease (MASLD), Tirzepatide inhibits the formation of fat in the liver by regulating key enzymes in lipid metabolism. Relevant clinical trials have shown that it can effectively reduce liver fat content, bringing new hope for the treatment of liver diseases. In addition, its scientific research value in the prevention and treatment of complications such as cardiovascular diseases and chronic kidney diseases is also being gradually explored, providing a new entry point for interdisciplinary research.

▶ On the industrial side, with the rapid expansion of the global metabolic disease market, the production and supply capacity of Tirzepatide has continued to improve, and its market performance has shown explosive growth. According to industry data, the annual sales of Tirzepatide soared to 36.507 billion US dollars in 2025, officially surpassing semaglutide to become the global "drug king". Among them, the sales of the hypoglycemic version (Mounjaro) were 22.965 billion US dollars, and the sales of the weight loss version (Zepbound) were 13.542 billion US dollars. They increased by 99% and 175% respectively year-on-year. At present, many domestic enterprises are accelerating the industrial production of Tirzepatide raw materials. Eli Lilly is also investing 1.5 billion yuan to expand its factory in Suzhou and promote the localization production process of "Made in China Tirzepatide". Some domestic enterprises have achieved breakthroughs in related technologies, supporting various modifications such as biotin labeling and fluorescence labeling. The product purity is over 99%, which can meet the personalized research and production needs and accelerate the localization process of this product.

▶ Industry experts say that the rise of Tirzepatide (2023788-19-2) has not only reshaped the treatment landscape of metabolic diseases, but also promoted the iterative upgrade of peptide drug research and development technology, marking that the global pharmaceutical market has officially entered the "metabolic era" from the "anti-cancer era". Its innovative mechanism of dual-target synergy provides a brand-new idea for the subsequent research and development of peptide drugs, and the explosive market growth also confirms the huge demand in the field of metabolic diseases. In the future, with the continuous deepening of scientific research and the continuous optimization of production technology, Tirzepatide will achieve breakthroughs in more metabolism-related disease fields. At the same time, the acceleration of the domestic production process will further reduce its application cost, injecting new impetus into the high-quality development of the global pharmaceutical and health industry.

▶ It is reported that a complete Tirzepatide supply chain system has gradually taken shape in the market, covering multiple links such as raw material production, formulation research and development, and supply of scientific research reagents. Relevant enterprises ensure that their products meet international standards through strict quality control systems, providing reliable support for clinical applications and scientific research work, and contributing to the continuous progress of global medical research and health.